Back to GetFilings.com



Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 

 
 
FORM 10-Q
 
 
(Mark One)
x
 
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended September 29, 2002
 
¨
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from                      to                     
 
Commission File Number 000-26137
 
 

 
 
drugstore.com, inc.
(Exact name of registrant as specified in its charter)
 
Delaware
 
04-3416255
(State or other jurisdiction
of incorporation or organization)
 
(IRS Employer
Identification No.)
 
13920 Southeast Eastgate Way, Suite 300
Bellevue, Washington 98005
(Address of principal executive offices)
 
(425) 372-3200
(Registrant’s telephone number, including area code)
 
 

 
 
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:  Yes  x  No   ¨.
 
As of November 4, 2002, the number of shares of the registrant’s Common Stock outstanding was 68,228,252.
 
 


Table of Contents
DRUGSTORE.COM, INC.
 
FORM 10-Q FOR THE QUARTER ENDED September 29, 2002
 
Table of Contents
 
    
Page

PART I.    FINANCIAL INFORMATION
    
Item 1.    Financial Statements (unaudited):
    
  
3
  
4
  
5
  
6
  
7
  
12
  
20
PART II.    OTHER INFORMATION
    
  
21
  
21
  
21
  
22
  
23

2


Table of Contents
 
PART I—FINANCIAL INFORMATION
 
Item 1.    Financial Statements
 
DRUGSTORE.COM, INC.
 
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
 
    
September 29,
2002

    
December 30,
2001

 
    
(unaudited)
        
Assets
                 
Current assets:
                 
Cash and cash equivalents
  
$
37,040
 
  
$
39,518
 
Marketable securities
  
 
25,201
 
  
 
39,238
 
Accounts receivable, net
  
 
14,613
 
  
 
10,171
 
Inventories
  
 
4,907
 
  
 
6,659
 
Prepaid marketing expenses
  
 
2,427
 
  
 
12,539
 
Other current assets
  
 
2,987
 
  
 
1,500
 
    


  


Total current assets
  
 
87,175
 
  
 
109,625
 
Fixed assets, net of accumulated depreciation of $28,785 and $23,492, respectively
  
 
17,988
 
  
 
23,948
 
Intangible assets, net
  
 
5,747
 
  
 
7,888
 
Goodwill, net
  
 
5,694
 
  
 
14,599
 
Prepaid marketing expenses
  
 
13,168
 
  
 
14,884
 
Deposits and other assets
  
 
378
 
  
 
354
 
    


  


Total assets
  
$
130,150
 
  
$
171,298
 
    


  


Liabilities and Stockholders’ Equity
                 
Current liabilities:
                 
Accounts payable
  
$
23,111
 
  
$
20,309
 
Accrued compensation
  
 
2,710
 
  
 
2,608
 
Accrued marketing expenses
  
 
2,400
 
  
 
2,249
 
Other current liabilities
  
 
1,650
 
  
 
2,031
 
Current portion of capital lease obligations
  
 
667
 
  
 
1,612
 
    


  


Total current liabilities
  
 
30,538
 
  
 
28,809
 
Capital lease obligations, less current portion
  
 
224
 
  
 
638
 
Stockholders’ equity:
                 
Preferred stock, $.0001 par value, 10,000,000 shares authorized, no shares outstanding
  
 
—  
 
  
 
—  
 
Common stock, $.0001 par value, stated at amounts paid in:
                 
250,000,000 authorized, 68,207,750 and 66,731,818 issued and outstanding
  
 
744,392
 
  
 
742,949
 
Deferred stock-based compensation
  
 
(889
)
  
 
(1,400
)
Accumulated deficit
  
 
(644,115
)
  
 
(599,698
)
    


  


Total stockholders’ equity
  
 
99,388
 
  
 
141,851
 
    


  


Total liabilities and stockholders’ equity
  
$
130,150
 
  
$
171,298
 
    


  


 
See accompanying notes to condensed consolidated financial statements.

3


Table of Contents
DRUGSTORE.COM, INC.
 
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
(unaudited)
 
    
Three Months Ended

    
Nine Months Ended

 
    
Sept. 29, 2002

    
Sept. 30, 2001

    
Sept. 29, 2002

    
Sept. 30, 2001

 
Net sales
  
$
47,352
 
  
$
34,978
 
  
$
138,903
 
  
$
101,782
 
Costs and expenses:
                                   
Cost of sales
  
 
38,018
 
  
 
29,001
 
  
 
111,800
 
  
 
85,261
 
Fulfillment and order processing(1)
  
 
6,633
 
  
 
6,556
 
  
 
19,800
 
  
 
21,239
 
Marketing and sales(2)
  
 
3,582
 
  
 
7,711
 
  
 
19,887
 
  
 
26,916
 
Technology and content(3)
  
 
2,516
 
  
 
4,970
 
  
 
9,326
 
  
 
15,530
 
General and administrative(4)
  
 
2,884
 
  
 
2,961
 
  
 
8,685
 
  
 
10,528
 
Impairment and restructuring charges
  
 
—  
 
  
 
7,667
 
  
 
2,450
 
  
 
14,961
 
Amortization of intangible assets
  
 
712
 
  
 
9,201
 
  
 
2,142
 
  
 
28,593
 
Amortization of stock-based compensation
  
 
258
 
  
 
1,417
 
  
 
1,366
 
  
 
5,866
 
    


  


  


  


Total costs and expenses
  
 
54,603
 
  
 
69,484
 
  
 
175,456
 
  
 
208,894
 
    


  


  


  


Operating loss
  
 
(7,251
)
  
 
(34,506
)
  
 
(36,553
)
  
 
(107,112
)
Interest income, net
  
 
300
 
  
 
847
 
  
 
1,041
 
  
 
3,780
 
Loss before cumulative effect of change in accounting principle
  
 
(6,951
)
  
 
(33,659
)
  
 
(35,512
)
  
 
(103,332
)
Cumulative effect of change in accounting principle
  
 
—  
 
  
 
—  
 
  
 
(8,905
)
  
 
(4,121
)
Extraordinary gain on renegotiation of equity guarantee
  
 
—  
 
  
 
7,500
 
  
 
—  
 
  
 
7,500
 
Net loss
  
$
(6,951
)
  
$
(26,159
)
  
$
(44,417
)
  
$
(99,953
)
    


  


  


  


Basic and diluted loss per share:
                                   
Loss before cumulative effect of change in accounting principle and extraordinary gain
  
$
(0.10
)
  
$
(0.50
)
  
$
(0.53
)
  
$
(1.57
)
Cumulative effect of change in accounting principle
  
 
—  
 
  
 
—  
 
  
 
(0.13
)
  
 
(0.06
)
Extraordinary Gain
  
 
—  
 
  
 
0.11
 
  
 
—  
 
  
 
0.11
 
    


  


  


  


    
$
(0.10
)
  
$
(0.39
)
  
$
(0.66
)
  
$
(1.52
)
Weighted average shares outstanding used to compute basic and diluted loss per share
  
 
68,130,576
 
  
 
66,261,576
 
  
 
67,588,023
 
  
 
65,890,933
 
    


  


  


  



(1)
 
Excludes amortization of stock-based compensation of $70 and $333 for the three and nine months ended September 29, 2002, respectively, and $264 and $1,062 for the three and nine months ended September 30, 2001, respectively.
(2)
 
Excludes amortization of stock-based compensation of $26 and $154 for the three and nine months ended September 29, 2002, respectively, and $205 and $834 for the three and nine months ended September 30, 2001, respectively.
(3)
 
Excludes amortization of stock-based compensation of $90 and $484 for the three and nine months ended September 29, 2002, respectively, and $555 and $2,077 for the three and nine months ended September 30, 2001, respectively.
(4)
 
Excludes amortization of stock-based compensation of $72 and $395 for the three and nine months ended September 29, 2002, respectively, and $393 and $1,893 for the three and nine months ended September 30, 2001, respectively.
 
See accompanying notes to condensed consolidated financial statements.

4


Table of Contents
DRUGSTORE.COM, INC.
 
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY
(in thousands, except share data)
(unaudited)
 
    
Common Stock

  
Deferred
Stock-Based Compensation

    
Accumulated Deficit

    
Total

 
    
Shares

  
Amount

        
Balance at December 30, 2001
  
66,731,818
  
$
742,949
  
$
(1,400
)
  
$
(599,698
)
  
$
141,851
 
Exercise of stock options
  
1,162,407
  
 
494
  
 
—  
 
           
 
494
 
Employee stock purchase plan
  
61,119
  
 
94
  
 
—  
 
  
 
—  
 
  
 
94
 
Issuance of common stock to settle fair market value guarantee
  
252,406
  
 
—  
  
 
—  
 
  
 
—  
 
  
 
—  
 
Deferred stock-based compensation, net of cancellations of $286
  
—  
  
 
855
  
 
(855
)
  
 
—  
 
  
 
—  
 
Amortization of stock-based compensation
  
—  
  
 
—  
  
 
1,366
 
  
 
—  
 
  
 
1,366
 
Net loss
  
—  
  
 
—  
  
 
—  
 
  
 
(44,417
)
  
 
(44,417
)
    
  

  


  


  


Balance at September 29, 2002
  
68,207,750
  
$
744,392
  
$
(889
)
  
$
(644,115
)
  
$
99,388
 
    
  </